Life sciences investor KDventures Q2 net loss widens on portfolio revaluations

Kdventures AB

28/08/2026 07:11

Overview
Sweden life sciences investor's Q2 net loss widened sharply on portfolio revaluations
Net asset value fell, mainly due to lower valuations for Umecrine Cognition and Dilafor
Company completed KDev Investments acquisition, simplifying structure and eliminating dividend liability

Outlook
Company expects results from Umecrine Cognition's Phase 1b/2a study in H2 2026
KDventures says simplified structure allows focus on value-driving events in portfolio
Company sees continued patient recruitment in Umecrine Cognition study as planned

Result Drivers
UMECRINE COGNITION REVALUATION - Co said a capital raise with new investors led to a new valuation point and a SEK 369.4 mln decrease in portfolio value for Umecrine Cognition
DILAFOR VALUATION REVIEW - Co said a revised valuation of Dilafor, based on updated assumptions, led to a SEK 326 mln decrease in portfolio value
DIVIDEND LIABILITY ELIMINATED - Acquisition of KDev Investments eliminated potential dividend to Rosetta, improving net fair value by SEK 320.2 mln

Company press release: ID:nMFN2cfnZr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 300,000
 
Q2 Loss Per Share
 
SEK 0.68
 
Q2 Net Loss
 
SEK 451 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Kdventures AB is SEK0.90, about 287.9% above its August 27 closing price of SEK0.23

Reuters Recommended Reads
Aug 26 - Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Aug 27 - Sweden's BioInvent Q2 net sales drop, loss widens
Aug 26 - Sweden's Modus Therapeutics narrows Q2 net loss, extends financing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)